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Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis: a systematic review and meta-analysis.   
 
ABSTRACT   
 
Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for 
use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from 
their well-documented therapeutic value, it is still uncertain to what extent they are associated with an 
increased risk of infectious adverse events. 
Areas covered: We conducted a systematic review and meta-analysis of published randomized studies 
to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious 
infections; tuberculosis; opportunistic infections; any infection). We searched Medline, Embase, and the 
Cochrane Library up to May 2014 to identify eligible studies in adult patients with rheumatoid arthritis, 
psoriatic arthritis, or ankylosing spondylitis that evaluated anti-TNF drugs compared with placebo or no 
treatment.  
Expert opinion: Our study encompassed data from 71 randomized controlled trials involving 22,760 
participants (range of follow-up: 1 to 36 months) and seven open label extension studies with 2,236 
participants (range of follow-up: 6 to 48 months). Quantitative synthesis of the available data found 
statistically significant increases in the occurrence of infections (20%), serious infections (40%), and 
tuberculosis (250%) associated with anti-TNF drug use, while the data for opportunistic infections were 
scarce. The quality of synthesized evidence was judged as moderate. Further evidence from registries 
and long-term epidemiological studies are needed to better define the relationship between anti-TNF 
agents and infection complications.  
 
Keywords: ankylosing spondylitis; anti-TNF drugs; drug safety; infections; meta-analysis; 
opportunistic infections; psoriatic arthritis; rheumatoid arthritis; serious infections; systematic review; 
tuberculosis.  
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Article highlights:  
 The association between anti-TNF drug use and infectious adverse events (AEs) is unclear.  
 The authors conducted a systematic review and meta-analysis of published trials involving 
patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis to determine the 
effect of anti-TNF agents on the risk of infectious AEs (serious infections, tuberculosis, 
opportunistic infections, or any infection).  
 71 RCTs with 22,760 patients, and seven OLE studies with 2,236 patients, met eligibility criteria 
and reported the occurrence of infectious AEs.  
 Synthesis of the evidence supports the hypothesis that the use of anti-TNF drugs significantly 
increases the risk of infectious AEs. The meta-analysis showed an increase in the occurrence of 
infections (20%), serious infections (40%), and tuberculosis (250%) associated with anti-TNF 
drug use, while the data for opportunistic infections were scarce. 
 Given the increasing use of TNF inhibitors in adult patients with rheumatoid arthritis, psoriatic 
arthritis, and ankylosing spondylitis, it is important to continue monitoring their safety profiles 
through complementary sources (e.g., registries, and long-term epidemiological studies).  
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1. Introduction  
 
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for clinical use in 
rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Adalimumab and 
golimumab are fully human monoclonal antibodies; infliximab is a chimeric monoclonal antibody with 
a murine variable region; certolizumab is a humanized Fab fragment conjugated to polyethylene glycol; 
and etanercept is a fusion protein of two TNFR2 receptor extracellular domains and the Fc fragment of 
human immunoglobulin 1 [1]. 
Apart from their well-documented therapeutic value for several diseases including rheumatoid arthritis 
(RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), it is still uncertain to what extent 
therapy with anti-TNF drugs may be associated with an increased risk of infectious adverse events 
(AEs). Post-marketing surveillance and observational studies provided the first indication that TNF 
inhibitors might be associated with an increased risk of serious infections [2,3]. Subsequently, a 
systematic review and meta-analysis of randomized controlled trials (RCTs), published in 2006, 
identified a statistically significant rise in the risk of infectious AEs in RA patients treated with 
infliximab and adalimumab (the odds ratio [OR] for serious infections was 2.0, with 95% confidence 
interval [CI]: 1.3 to 3.1) [4]. However, observational studies have been inconsistent on this issue with 
reports of both increased risk [5-9] and of no increased risk [10-12]. 
Considering the conflicting results published in the literature, the high number of RCTs that have been 
performed since 2006, and the increasing use of TNF inhibitors as induction or maintenance treatment 
for adult patients with RA, PsA, or AS, we conducted a systematic review and meta-analysis of 
published trials to determine the occurrence of infectious AEs associated with use of anti-TNF agents. 
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2. Methods  
 
2.1 Protocol and registration 
Our study protocol [13] is registered on PROSPERO, the international prospective register of systematic 
reviews. The current systematic review and meta-analysis was performed according to the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement [14]. 
 
2.2 Data sources and search strategy 
A comprehensive search of MEDLINE and EMBASE bibliographic databases was conducted through 
May 2014. The following search terms were used: adalimumab, golimumab, infliximab, certolizumab 
pegol, etanercept, anti-tumo(u)r necrosis factor(s), tumo(u)r necrosis factor(s), tumo(u)r necrosis factor 
alpha antibody(ies), tumo(u)r necrosis factor antibody(ies), anti-TNF, TNF, biologic(al) agent(s), or 
biologic(s), combined with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. The 
search was limited to RCTs and humans. No language, date, or publication status restrictions were 
applied. We also searched the Cochrane Library for any RCT included in the Cochrane Central Register 
of Controlled Trials, and for any systematic review on the subject. 
Results were exported and compiled into a common reference database using EndNote. References were 
then de-duplicated to derive a unique set of records. Two investigators independently examined the 
search results and screened the titles and abstracts to exclude clearly irrelevant reports. The full text of 
the selected articles was critically evaluated for eligibility, and their reference lists (and of relevant 
reviews and meta-analyses) were manually scanned to identify further eligible studies. Experts were 
consulted for additional evidence, but there was no search for unpublished studies or data. 
 
2.3 Study selection and data extraction 
We considered RCTs or open label extension (OLE) studies that evaluated an anti-TNF agent 
(adalimumab, certolizumab, etanercept, golimumab, or infliximab) as induction or maintenance therapy 
for adults with RA, PsA or AS, and reported the occurrence of infectious AEs. Eligible outcomes were: 
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any infection, serious infections (infections that require antimicrobial therapy and/or hospitalization), 
tuberculosis, or opportunistic infections. We included studies that evaluated an anti-TNF therapy 
compared with placebo or no treatment, or multi-interventional therapies where the effect of anti-TNF 
treatment could be separated out (i.e. add-on to conventional disease-modifying anti-rheumatic drugs). 
In case of multiple publications from the same study, we selected the most updated one and extracted 
the data for the maximum follow-up time. OLE studies were eligible if they represented an extension of 
previous RCTs, and reported infectious AEs according to the group to which the patients were originally 
randomized. 
Data extraction was undertaken by independent reviewers. Any discrepancy was resolved by consensus, 
referring back to the original article. The following data were extracted from each study: first author’s 
last name, journal and year of publication, trial’s acronym, study design and duration, number of 
participants, disease studied (RA, PsA, or AS), patient characteristics (age, concomitant treatments, 
duration of disease), intervention parameters (drug, dose, administration), and numbers of participants 
with events (serious infection; tuberculosis; opportunistic infection; or any infection) reported for the 
intervention and control groups. 
 
2.4 Assessment of risk of bias 
We evaluated the risk of bias (RoB) in included studies using the Cochrane Collaboration’s tool [15,16], 
which addresses the following domains: sequence generation; allocation concealment; blinding; 
incomplete outcome data; and other sources of bias, such as extreme baseline imbalances in prognostic 
variables, selective crossover bias (i.e. subsequent anti-TNF treatment in the control groups), etc. These 
items were considered for the RoB assessment and were classified as “adequate” (low RoB), 
“inadequate” (high RoB), or “unclear”. We considered only the information that was available in the 
full-text publications. Studies with adequate procedures in all domains were considered to have a low 
RoB; ones with inadequate procedures in one or more domains were considered to have a high RoB; 
and those with unclear procedures in one or more domains were considered to have unclear RoB. 
Discrepancies among reviewers were discussed, and agreement was reached by consensus. 
On the other hand, OLE studies have higher RoB than the original trials. The study populations are no 
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longer randomly allocated, they are not blinded, and usually represent only a proportion of the 
participants recruited in the original trial (e.g., those with an adequate drug response and tolerance during 
the original study period). Therefore, we decided a priori that the items related to sequence generation, 
allocation concealment, masking of participants, personnel and outcome assessors, and incomplete 
outcome data, should be rated as high RoB in the OLE study assessment. 
 
2.5 Data synthesis and analysis 
OR was the metric of choice in all comparisons. Study-level ORs and their 95% CIs were calculated by 
reconstructing contingency tables based on the number of participants randomly assigned and the 
number of participants with the events of interest (analysis by intention to treat). When no events 
occurred in one group of the trial, we used a continuity correction that was inversely proportional to the 
relative size of the opposite group. In particular, the continuity correction for the treatment group was 
1/(R+1), where R is the ratio of control group to treatment group sizes. Similarly, the continuity 
correction for the control group was R/(R+1). This methodological approach outperforms the use of a 
constant continuity correction of 0.5 in a setting of sparse data and imbalanced study groups [17]. Trials 
reporting zero-event data for both study groups were excluded from the analysis. 
We used two techniques to calculate the pooled effect estimates: the fixed-effects model (Mantel-
Haenszel approach [18]) and the random-effects model (DerSimonian & Laird approach [19]). In the 
absence of heterogeneity, the fixed- and the random-effects model provide similar results. When 
heterogeneity is found, the random-effects model might be more prudent, though both techniques may 
be biased.  
After the overall meta-analysis, we conducted subgroup analyses by the anti-TNF drug (adalimumab, 
golimumab, infliximab, certolizumab, or etanercept) to investigate potentially different effects on risk. 
To assess any association between dose of TNF inhibitors and risk of infectious AEs, we also conducted 
a sensitivity analysis using (from the multi-arm trials) only the data referring to the intervention arms 
exposed to the highest doses. When no events were reported, the highest dose arm was merged with the 
second, the third highest, etc., in order to produce a group with at least one event, and include the study 
in the particular analysis. Full data were used from the two-arm trials. 
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Finally, we performed meta-regression analyses to investigate the impact of certain trial characteristics 
on the effect estimates. We converted all ORs by logarithmic transformation to achieve more 
symmetrical distributions. The natural logarithm of the OR was the dependent variable, and (i) age of 
participants enrolled and (ii) duration of follow-up were entered as covariates. This analysis was an 
indirect way to deal with aspects such as the possibility of effect modification by age, and to examine 
for increasing or decreasing risks with increasing duration of drug use, a feature associated with causal 
relationships. We applied a weighted regression model, so that the more precise studies have more 
influence in the analysis.  
Regarding the open-label extension studies, their usefulness for generating reliable and valid data has 
been repeatedly challenged in the literature [20,21]. To avoid any biased or spuriously precise results, 
we did not include OLEs in our primary meta-analyses but synthesized their data separately. 
Selective outcome reporting or publication bias was assessed using the funnel plot, Begg’s test [22], and 
Egger’s test [23]. The between-study heterogeneity was evaluated using Cochran’s Q test [24] with a 
0.10 level of significance. We also calculated the I-squared statistic [25], which describes the percentage 
variation across studies that is due to heterogeneity rather than chance. Negative values of I-squared 
were put equal to zero, so that I-squared lies between 0% and 100%. An I-squared value less than 40% 
was considered as indicative of “not important heterogeneity” and a value over 75% as indicative of 
“considerable heterogeneity” [26].  
The quality of the meta-analytic evidence for each of the outcomes was assessed using GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) [27]. 
For all statistical analyses, we used Stata 11 software (Stata Corp., College Station, Texas, USA), and 
the R software environment [28], version 3.1.1, and the “meta” package for R [29], version 3.8-0. All 
p-values are two-tailed. For all tests (except for heterogeneity), a p-value less than 0.05 was regarded as 
statistically significant.  
 
2.6 Role of the funding source 
This study was supported by an unrestricted grant from Pfizer Italia. The funding source had no role in 
the design and conduct of the study; collection, management, analysis, or interpretation of the data; 
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preparation, review, or approval of the manuscript; and decision to submit it for publication.  
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3. Results  
 
3.1 Search results 
A summary of the evidence search and selection process is shown in Figure 1, and in the Appendix. 
Seventy-one RCTs [30-100] met the eligibility criteria and reported the occurrence of infectious AEs 
(serious infection, tuberculosis, opportunistic infection, or any infection) during the study period; we 
were thus able to conduct a post hoc analysis of these trials, calculate ORs for the outcomes of interest 
according to the intention-to-treat principle, and incorporate them in the meta-analyses.  
These 71 RCTs evaluated infliximab (n=16), adalimumab (n=22), golimumab (n=11), certolizumab 
pegol (n=7), or etanercept (n=15) as induction or maintenance treatments for adult patients with RA 
(n=46), PsA (n=9), or AS (n=16). A total of 22,760 individuals participated in these trials; 14,766 in 
treatment groups, and 7,994 in control groups.  
Substantial imbalance was observed between the treatment and control group sizes within studies 
(median ratio, 2:1; maximum ratio, 7:1). The mean age of participants ranged from 30 to 62 years, and 
follow-up times from 1 to 36 months, between studies. A total experience of approximately 15,100 
person-years was reached (8 months per patient, on average). The publication dates of these trials ranged 
from 1999 to 2014. A summary of the trials’ characteristics is given in Table 1.  
Though most of the OLE studies were excluded because they did not report infectious AEs per study 
arm, we identified seven eligible OLEs [42,56,101-105] involving 2,236 participants. Their follow-up 
times ranged from 6 to 48 months. The outcomes of interest were reported according to the group to 
which patients were originally randomized, so we could calculate ORs and synthesize the evidence.  
 
3.2 Risk of bias in the studies included in meta-analysis  
Random sequence generation: 11 of 71 RCTs (15.5%) reported adequate methods for sequence 
generation and were judged to be at low RoB. Information in 60 trials (84.5%) was insufficient to permit 
judgement (i.e. unclear RoB). 
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Allocation concealment: 33 of 71 RCTs (46.5%) reported adequate methods for allocation concealment 
(low RoB). In 38 trials (53.5%) information was insufficient (unclear RoB). 
Blinding of participants and personnel: 20 of 71 RCTs (28.2%) were double-blind, three were not 
(4.2%), while for the other 48 trials (67.6%) information was insufficient. 
Blinding of outcome assessment: In 26 of 71 RCTs (36.6%) the outcome assessment was blind, one was 
not blind (1.4%), while for the other 44 trials (62.0%) information was insufficient. 
Incomplete outcome data: 49 of 71 RCTs (69.0%) were judged to be at high RoB. Fifteen trials (21.1%) 
were judged to be at low RoB, while for seven (9.9%) information was insufficient. 
Other sources of bias: Nine studies (12.7%) suffered selective crossover across groups (high RoB). 
Overall, the assessment indicated high RoB across 51 of the 71 included RCTs (71.8%) and unclear 
RoB for 19 RCTs (26.8%). Quality assessment items are presented in Figure 2. Regarding the OLE 
studies’ assessment, all studies were rated as high RoB.  
 
3.3 Results of meta-analyses  
3.3.1 Serious infections  
Fifty-eight RCTs [30-32,34-38,40-49,51-58,60-76,78,79,81,82,84-89,91,94,95,99,100] involving 
20,796 adult patients with RA, PsA, or AS, evaluated anti-TNF drugs and reported the occurrence of 
serious infections (2.6% in treatment groups; and 2.0% in control groups). Exposure to anti-TNF agents 
was associated with increased risk of serious infectious AEs, under both a fixed-effects model (OR: 
1.41, 95% CI: 1.16, 1.73) and a random-effects model (OR: 1.25, 95% CI: 1.01, 1.55) (Table 2). The 
ORs with their 95% CIs for the individual trials, and the pooled results are presented in a forest plot 
(Figure 3).  
Cochran’s Q test had a p-value of 0.78 and the corresponding I-squared statistic was 0%, both indicating 
very little variability between studies. In contrast, the p-values for the Begg’s test (p=0.06) and the 
Egger’s test (p=0.09) suggested a possible bias. Indeed, there was a funnel plot asymmetry, with the left 
corner of the pyramidal part of the funnel missing (Figure 4A). Small studies reporting relative risks 
lower than the unity are probably missing, and thus the estimated pooled OR for serious infections may 
have been overestimated.  
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The subgroup analysis investigating potentially different effects on risk by the anti-TNF drugs 
(adalimumab, golimumab, infliximab, certolizumab, or etanercept; Figure 3) was statistically 
significant under the fixed-effects model (p=0.05), while it was not under the random-effects model 
(p=0.14), suggesting that etanercept and golimumab might have a better safety profile for serious 
infections, with point effects estimates closer to 1.0 (Figure 3).  
To assess any association between higher doses of TNF inhibitors and risk of serious infections, we 
conducted a sensitivity analysis. The results did not materially change (fixed-effects, OR: 1.46, 95% CI: 
1.19, 1.79; random-effects, OR: 1.36, 95% CI: 1.09, 1.69) (Table 2). 
Meta-regression analysis, using the age of participants and the duration of follow-up as covariates, did 
not reveal any significant association (univariate analysis: age, p=0.72; duration of follow-up, p=0.21; 
and in multivariate analysis: age, p=0.69; duration of follow-up, p=0.20).  
The quantitative synthesis of six open-label extension phases of RCTs [42,56,101,103-105] did not 
provide any further evidence for the association between anti-TNF drugs and serious infections. The 
calculated summary effect estimate was not statistically significant assuming either a fixed-effects 
model (OR: 1.33, 95% CI: 0.77, 2.29) or a random-effects model (OR: 1.19, 95% CI: 0.68, 2.07). We 
found no evidence of selective outcome reporting or publication bias, or heterogeneity among the OLE 
studies (Table 2). 
 
3.3.2 Tuberculosis  
Nineteen RCTs [33,43,46,48,51,52,54,57,59,62,67,73,75,81,84,93,94,99,100] involving 8,320 adults 
with RA, PsA, or AS, evaluated anti-TNF drugs and reported the occurrence of tuberculosis; it was 0.6% 
in the treatment groups (5,339 patients; 32 events), while no event was reported in the control groups 
(2,981 patients). Thus, continuity corrections (inversely proportional to the relative size of the opposite 
arm) were used in the analysis. Exposure to anti-TNF agents was associated with a statistically 
significant 3-fold increase in the risk of tuberculosis (fixed-effects model, OR: 3.53, 95% CI: 1.58, 7.85; 
random-effects model, OR: 3.29, 95% CI: 1.48, 7.33) (Table 2). The ORs with their 95% CIs from the 
individual trials, and the pooled results, are presented in Figure 5. We found suggestive evidence of 
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selective outcome reporting or publication bias, but no heterogeneity among studies (Table 2).  
The subgroup analysis by the type of anti-TNF drug (Figure 5) did not reveal any difference among the 
drug-specific effect estimates (tests for subgroup differences: fixed effects, p=0.98; random effects, 
p=0.99). However, the power of this analysis is typically low, and, therefore, we cannot exclude 
clinically important differences between anti-TNF drugs treatment and progression of tuberculosis.  
In the sensitivity analysis conducted to assess any association between higher doses of TNF inhibitors 
and risk of tuberculosis, the results did not materially change (fixed-effects, OR: 3.32, 95% CI: 1.54, 
7.15; random-effects, OR: 3.23, 95% CI: 1.50, 6.98) (Table 2).  
Meta-regression analysis, using the age of participants and the duration of follow-up as covariates, did 
not reveal any association (univariate analysis: age, p=0.89; duration of follow-up, p=0.98; and in 
multivariate analysis: age, p=0.87; duration of follow-up, p=0.93).  
 
3.3.3 Opportunistic infections  
Only six RCTs [35,43,63,66,73,84] involving 3,886 adult patients reported the occurrence of 
opportunistic infections (0.3% in treatment groups; 0.3% in control groups). The association between 
anti-TNF drug use and the risk of opportunistic infections was neutral (fixed-effects, OR: 0.94, 95% CI: 
0.33, 2.64; random-effects model, OR: 0.81, 95% CI: 0.23, 2.87). The ORs with their 95% CIs from the 
individual trials, and the pooled results, are presented in Figure 6. We found no evidence of 
heterogeneity among the studies, selective outcome reporting or publication bias (Table 2).  
The subgroup analysis, investigating potentially different effects on risk between types of anti-TNF 
drugs, did not reveal any difference among the drug-specific effect estimates. However, the power of 
this analysis was considerably low. Moreover, the sensitivity analysis did not suggest association 
between higher doses of the anti-TNF drugs and the risk of developing opportunistic infections (Table 
2).  
 
3.3.4 Any infection  
In this analysis, 37 trials [31,32,34-37,39,42-45,47,50-53,55-57,60,62,64,65,67-
69,71,72,74,79,84,87,92,93,97-99] involving 12,796 adult patients with RA, PsA, or AS, were 
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incorporated. They examined anti-TNF agents and reported “the number of patients with at least one 
infection during the study” (frequency was 30.8% for the treatment groups, and 28.5% for control 
groups). Exposure to TNF inhibitors was associated with increased risk of any infectious AE (fixed-
effects, OR: 1.20, 95% CI: 1.10, 1.30; random-effects, OR: 1.20, 95% CI: 1.06, 1.36) (Table 2). The 
ORs with their 95% CIs from the primary studies, and the pooled results, are shown in Figure 7.  
The Cochran’s Q test had a p-value lower than 0.01 and the corresponding I-squared was 46%, both 
indicating important heterogeneity between studies. In contrast, the funnel plot (Figure 4B), along with 
Begg’s test (p=0.95) and Egger’s test (p=0.75), showed no evidence of selective outcome reporting or 
publication bias.  
The subgroup analysis by the type of anti-TNF drugs (Figure 7) did not reveal a significant difference 
among the drug-specific effect estimates (tests for subgroup differences: fixed effects, p=0.78; random 
effects, p=0.76).  
The sensitivity analysis performed to assess any association between higher doses of TNF inhibitors and 
risk of any infection, confirmed the results reported above (fixed-effects, OR: 1.21, 95% CI: 1.11, 1.32; 
random-effects, OR: 1.22, 95% CI: 1.07, 1.39) (Table 2).  
Importantly, in the meta-regression analysis, we obtained an estimate that was statistically significantly 
different from zero for the regression coefficient of the duration of follow-up (months) 
(coefficient=0.023; se=0.011; p=0.037; Figure 8). The between-trial heterogeneity was reduced by 17% 
when duration of follow-up was included as an explanatory variable in the model. The results did not 
substantially change when we included both the age of participants (p=0.88) and duration of follow-up 
(coefficient=0.023; se=0.011; p=0.039) in the model. This finding suggests that treatment with anti-TNF 
agents is associated with an increasing risk of infectious AEs, as duration of follow-up increases. 
Synthesis of six OLE studies [42,56,101-104] with longer follow-up periods (range: 6 to 48 months) 
provided further evidence for the association between anti-TNF drug use and risk of any infectious AEs 
(fixed-effects, OR: 1.69, 95% CI: 1.31, 2.18; random-effects, OR: 1.56, 95% CI: 1.05, 2.33) (Table 2). 
We found no evidence of heterogeneity among the OLEs, selective outcome reporting, or publication 
bias (Table 2). 
 
 –15– 
3.4 Quality of the evidence  
In this meta-analysis, the quality of synthesized evidence is rated as “moderate” for the following 
reasons: (i) the evidence was derived from RCTs (randomized study design is considered the gold 
standard for assessing drugs); (ii) the meta-analytic effect estimates are precise (except for opportunistic 
infections); (iii) the results are consistent (heterogeneity was low or moderate across studies); and (iv) 
the vast majority of the RCTs included in our study are characterized by high or unclear RoB, as assessed 
with the Cochrane Collaboration’s tool (a fact that downgrades the quality of evidence). A moderate 
quality of evidence means that we are moderately confident in the effect estimate. The true effect is 
likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  
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4. Conclusion 
This systematic review encompassed data from 71 published RCTs involving 22,760 adult patients with 
rheumatologic disease (range of follow-up: 1 to 36 months), and from seven OLE studies with 2,236 
patients (range of follow-up: 6 to 48 months). Quantitative synthesis of the available evidence supports 
the hypothesis that the use of anti-TNF drugs significantly affects the risk of infectious AEs. In 
particular, we found an increase in the occurrence of infections (20%), serious infections (40%), and 
tuberculosis (250%) associated with anti-TNF drug use, while the data for the opportunistic infections 
were scarce. Using the GRADE system [28], a summary of findings and strength of evidence is shown 
in Table 3.  
Over the last years, use of anti-TNF drugs by rheumatologic patients has been constantly increasing, 
and evidence on their safety continues to be collected [106]. Given the uncertainty on the effect of these 
agents on the risk of infectious AEs, we undertook a systematic review and meta-analysis on the topic.  
Seventy-one RCTs with 22,760 adult patients met the eligibility criteria and reported the occurrence of 
infectious AEs, as a secondary (safety) endpoint. Study-level relative risk estimates were calculated, in 
accordance with the intention-to-treat principle, and were appropriately synthesized. Our results provide 
relevant evidence that the use of anti-TNF drugs significantly affects the risk of infectious AEs. Similar 
results were noted when we analyzed for higher drug doses or synthesized the seven eligible OLE 
studies. Thus, the findings of the present meta-analysis are in line with several observational studies 
reporting a significant rise in the risk of infectious AEs associated with anti-TNF drug use [5-9].  
In 2006, Bongartz et al. published the first meta-analysis on this topic [4]. They identified a two-fold 
increase in the risk of serious infections associated with anti-TNF drugs (OR: 2.0, 95% CI: 1.3, 3.1), 
and an even higher increase when the analysis was restricted to high-dose groups vs. placebo (OR: 2.3, 
95% CI: 1.5, 3.6). Since then, several meta-analyses have been published with conflicting results. 
Leombruno et al. [107] analyzed 18 RCTs involving over 8,800 RA patients treated over an average of 
0.8 years. They did not identify an increased risk of serious infections (OR: 1.21, 95% CI: 0.89, 1.63). 
However, high-dose therapy was associated with a two-fold increase in the risk of serious infections. In 
2010, Bernatsky et al. [108] published a meta-analysis of seven observational studies involving RA 
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patients. Anti-TNF therapy appeared to significantly increase the risk of serious infections (OR: 1.37, 
95% CI: 1.18, 1.60). In 2011, Thompson et al. [109] conducted a meta-analysis of six RCTs and showed 
no increased risk of serious infection in patients with early RA receiving anti-TNF therapy (OR: 1.28, 
95% CI: 0.82, 2.00). As compared to those studies, our meta-analysis uses a much broader evidence 
base, includes a large number of trials (n=71), and provides updated evidence that can be appropriately 
integrated into relevant clinical guidelines. 
This study has some limitations. Firstly, our search was restricted to published studies and we did not 
search for unpublished/original data. Secondly, the trials included in our review are characterized by 
high or unclear RoB, as assessed with the Cochrane Collaboration’s tool. This is of concern, because 
the quality of the meta-analysis depends on the quality of the primary studies; if they are biased, then 
the meta-analysis will be biased as well. However some studies were rated at low risk of bias, and the 
estimates from studies at low risk did not differ from studies at high risk of bias. This increases the 
overall confidence we have in the final estimates. Thirdly, because duration of follow-up was up to 36 
months, risk estimates resulting from longer exposure to anti-TNF agents are not possible. Given the 
meta-regression finding that anti-TNF drug therapy is associated with higher risks of infectious AEs as 
duration of follow-up increases, evidence describing infection risk during longer durations of anti-TNF 
therapy is required. However, the present study also has merits. It was conducted using a rigorous and 
extensive bibliographic search that allowed the inclusion of all relevant published RCTs. Furthermore, 
the relatively precise meta-analytic effect estimates, the absence of significant between-study 
heterogeneity, and the stability of the results in the subgroup and sensitivity analyses, strengthen our 
confidence in the accuracy of our findings. 
 
5. Expert opinion 
The results of our meta-analyses raise concerns about the use of anti-TNF in patients with infectious 
diseases. Included trials carefully excluded patients with histories of infections such as latent 
tuberculosis. Even after careful selection of patients for inclusion, our meta-analysis provides definitive 
evidence that anti-TNF drugs can disturb physiological cytokine-mediated signaling. The tuberculosis 
meta-analysis is paradigmatic. All events were in the anti-TNF arms, while the control arms were 
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tuberculosis free. There are several prospective and retrospective studies exploring the association 
between anti-TNFs and tuberculosis [110-115]. The annual incidence rate varied depending on the 
country observed and the anti-TNF drug administered. Therefore, it is important to establish accurate 
latent tuberculosis infection screening strategy before commencing anti-TNF therapy in patients with 
immune-mediated inflammatory diseases [116]. The implementation of recommendations for latent 
tuberculosis infection screening and (prophylactic) treatment before initiation of anti-TNF therapy might 
reduce the infection incidence. Risk stratification scores associated with host demographic and clinical 
features, and previous or current non-biologic therapies are warranted to support the decision to start a 
treatment and the safest biologic choice [117]. For all anti-TNF drugs, the tuberculosis incidence rate 
was consistently higher than that in the general population, but infliximab and adalimumab were 
associated with the highest incidence rates when compared to etanercept [118]. Despite all anti-TNF 
neutralize TNF resulting in disruption of the granuloma that normally compartmentalizes 
Mycobacterium tuberculosis, etanercept might have a different impact on immunity that may allow the 
granuloma to reconstitute itself, thus preventing bacillary dissemination [119]. Our review did not 
identify substantial differences among the anti-TNFs drugs. However, the power of these subgroup 
analyses is typically limited: up to two cases of tuberculosis were included in trials exploring etanercept 
and golimumab, an inadequate number to demonstrate a definite association between the use of the drug 
and reactivation tuberculosis. Additionally concomitant corticosteroid and methotrexate therapies might 
be important confounding factors, hiding differences on drug inflammatory mechanisms and safety 
profile. 
Given the increased risk of reoccurrence of infections, rheumatologists should further consider that the 
number of patients experiencing these adverse events is higher in studies other then RCTs such that the 
clinical consequences of the treatment might be more severe. There is not clear hypothesis for assuming 
that harms are different in directions or magnitude of effects across diseases, so we did not group studies 
by disease. We hypothesized that there were not strong differences in the case mix of patients across 
populations included in the RCTs, so harms, overall, should have been fairly consistent across studies. 
However there was some heterogeneity, so some differences between patient populations cannot be 
excluded. 
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In conclusion, synthesis of existing evidence from RCTs involving rheumatologic patients confirms that 
anti-TNF drug use significantly increases the risk of infectious AEs, especially the risk for serious 
infections and tuberculosis. Given the increasing use of anti-TNF agents in adult patients with RA, PsA, 
or AS, it is important to continue monitoring their safety profiles, through complementary sources of 
research data, such as registries and long-term epidemiological studies.  
 –20– 
 
Acknowledgements  
We are grateful to Dr Antonio Spadaro who participated in the early phase of this study. Unfortunately, 
he passed away before seeing the completion of the review.  
 
 
 
 
Declaration of interest 
 
This study was supported by an unrestricted grant from Pfizer Italia through a service agreement with 
Health Publishing & Services Srl. Health Publishing & Services Srl supports research activities at the 
IRCCS Galeazzi Orthopedic Institute and the IRCCS Mario Negri Institute for Pharmacological 
Research. Valentina Marino is an employee of Pfizer Italia. All the other authors declare no conflict of 
interest related to the article.  
 
 
 –21– 
 
References 
[1] Thalayasingam N, Isaacs J. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25:549-67  
[2] Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor 
necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a 
multicenter active surveillance report. Arthritis Rheum 2003;48:2122-7 
[3] Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with 
tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5 
[4] Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis 
and the risk of serious infections and malignancies: systematic review and meta-analysis of rare 
harmful effects in randomized controlled trials. JAMA 2006;295:2275-85 ** First published 
meta-analysis on the topic. It demonstrated a 100% increase in the risk of serious 
infections among anti-TNF drug users.   
[5] Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis 
patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33 
[6] Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in 
rheumatoid arthritis. Rheumatology 2007;46:1157-60 
[7] Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha 
blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 
patients. Rheumatology 2007;46:327-34 
[8] Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated 
with biologic agents. Arthritis Rheum 2005;52:3403-12 
[9] Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in 
rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor 
antagonists. Ann Rheum Dis 2007;66:880-5 
 –22– 
[10] Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of 
hospitalization for pneumonia: associations with prednisone, disease-modifying anti-rheumatic 
drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:628-34 
[11] Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and 
the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis 
Rheum 2007;56:1754-64 
[12] Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and 
bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis 
factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis 
Rheum 2006;54:2368-76 
[13] Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis and 
ankylosing spondylitis: a systematic review and meta-analysis. PROSPERO 
2014:CRD42014009993. Available at: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014009993 [Last 
accessed 7 February 2016] 
[14] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64 
[15] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing 
risk of bias in randomised trials. BMJ 2011;343:d5928 
[16] Bonovas S, Lytras T, Nikolopoulos G. On the criteria used for assessing the risk of bias in 
randomized trials included in systematic reviews and meta-analyses addressing adverse effects. 
Eur J Epidemiol 2015;30:249-50 
[17] Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity 
corrections in meta-analysis of sparse data. Stat Med 2004;23:1351-75  
[18] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of 
disease. J Natl Cancer Inst 1959;22:719-48 
[19] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88 
 –23– 
[20] Cho MK. Open-label extension studies: are they really research? Am J Bioeth 2014;14:60-1  
[21] Day RO, Williams KM. Open-label extension studies: do they provide meaningful information 
on the safety of new drugs? Drug Saf 2007;30:93-105 
[22] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. 
Biometrics 1994;50:1088-101 
[23] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 
graphical test. BMJ 1997;315:629-34 
[24] Cochran WG. The combination of estimates from different experiments. Biometrics 
1954;810:101-29 
[25] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 
BMJ 2003;327:557-60 
[26] Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. 
The Cochrane Collaboration; 2011, version 5.0.1 
[27] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of 
evidence and strength of recommendations. BMJ 2008;336:924-6 
[28] R Development Core Team. R: A Language and Environment for Statistical Computing. 
Vienna, Austria: R Foundation for Statistical Computing; 2014. Available at: http://www.R-
project.org/ [Last accessed 7 Feb 2016] 
[29] Schwarzer G. meta: An R package for meta-analysis. R News 2007;7:40-5 
[30] Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after 
treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis 
(PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29  
[31] Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms 
of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind 
randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39-47 
 –24– 
[32] Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and 
symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind 
randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55 
[33] Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen 
versus naproxen alone in patients with early, active axial spondyloarthritis: results from the 
double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101-7 
[34] Huang F, Gu J, Zhu P, et al. Efficacy and safety of adalimumab in Chinese adults with active 
ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 2014;73:587-
94 
[35] Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal 
antibody, outcome study for the prevention of joint damage in Japanese patients with early 
rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis 2014;73:536-43 
[36] Takeuchi T, Harigai M, Tanaka Y, et al. Golimumab monotherapy in Japanese patients with 
active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: 
results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO 
study through 24 weeks. Ann Rheum Dis 2013;72:1488-95 
[37] Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol 
in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC 
phase IIIb study. Rheumatology (Oxford) 2012;51:2204-14 
[38] van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo 
in rheumatoid arthritis. N Engl J Med 2012;367:508-19 
[39] Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients 
with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial 
(ABILITY-1). Ann Rheum Dis 2013;72:815-22 
[40] Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on 
combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, 
 –25– 
randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 
2013;72:851-7 
[41] Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 
weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone 
for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-
initiated study. Ann Rheum Dis 2013;72:844-50 
[42] Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, et al. Intravenous golimumab is effective in 
patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as 
week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-
FURTHER trial. Ann Rheum Dis 2013;72:381-9 
[43] Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic 
consequences of achieving stable low disease activity and remission with adalimumab plus 
methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the 
randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71 
[44] Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 
weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 
(Oxford) 2012;51:1226-34 
[45] Tanaka Y, Harigai M, Takeuchi T, et al. Golimumab in combination with methotrexate in 
Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum 
Dis 2012;71:817-24 
[46] Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to 
methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the 
RESPOND study. Ann Rheum Dis 2012;71:541-8 
[47] Fleischmann R, Cutolo M, Genovese MC, et al. Phase Iib dose-ranging study of the oral JAK 
inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with 
active rheumatoid arthritis with an inadequate response to disease-modifying anti-rheumatic 
drugs. Arthritis Rheum 2012;64:617-29 
 –26– 
[48] van Vollenhoven RF, Kinnman N, Vincent E, et al J. Atacicept in patients with rheumatoid 
arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-
controlled trial. Arthritis Rheum 2011;63:1782-92 
[49] Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the 
prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69:1926-8  
[50] Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebo-
controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the 
HEEL trial. Ann Rheum Dis 2010;69:1430-5.  
[51] Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor 
alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-
eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-
controlled study. Arthritis Rheum 2010;62:917-28 
[52] Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis 
factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-
naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, 
multicenter, randomized, double-blind, placebo-controlled study of golimumab before 
methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 
2009;60:2272-83  
[53] Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after 
treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, 
randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21  
[54] Chen DY, Chou SJ, Hsieh TY, et al. Randomized, double-blind, placebo-controlled, 
comparative study of human anti-TNF antibody adalimumab in combination with methotrexate 
and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med 
Assoc 2009;108:310-9 
[55] Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha 
antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: 
 –27– 
Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. 
Arthritis Rheum 2009;60:976-86 
[56] Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour 
necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis 
despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96 
[57] Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus 
methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. 
Ann Rheum Dis 2009;68:797-804 
[58] Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab 
pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-
modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11  
[59] Keystone E, Heijde Dv, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly 
more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-
two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group 
study. Arthritis Rheum 2008;58:3319-29 
[60] Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with 
ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III 
trial. Arthritis Rheum 2008;58:3402-12 
[61] Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis 
factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. 
Arthritis Rheum 2008;59:1467-74 
[62] Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of 
combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid 
arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009;68:1146-52 
[63] Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a 
combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid 
 –28– 
arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-
82  
[64] Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis 
despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-
ranging study. Arthritis Rheum 2008;58:964-75 
[65] Miyasaka N; CHANGE Study Investigators. Clinical investigation in highly disease-affected 
rheumatoid arthritis patients in Japan with adalimumab applying standard and general 
evaluation: the CHANGE study. Mod Rheumatol 2008;18:252-62 
[66] Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs 
placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled 
study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann 
Rheum Dis 2008;67:1096-103 
[67] van der Heijde D, Klareskog L, Landewé R, et al. Disease remission and sustained halting of 
radiographic progression with combination etanercept and methotrexate in patients with 
rheumatoid arthritis. Arthritis Rheum 2007;56:3928-3 
[68] Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded 
study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant 
comorbid diseases. Rheumatology (Oxford) 2007;46:1122-5 
[69] Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment 
of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. 
J Rheumatol 2007;34:1040-50 
[70] Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully 
human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin 
Pharmacol 2007;47:383-96 
[71] van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective 
as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7 
 –29– 
[72] van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients 
with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-
controlled trial. Arthritis Rheum 2006;54:2136-46 
[73] Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background 
reatments, among patients with rheumatoid arthritis and various comorbidities: a large, 
randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86 
[74] Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo 
controlled trial of infliximab combined with low dose methotrexate in Japanese patients with 
rheumatoid arthritis. J Rheumatol 2006;33:37-44 
[75] Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, 
randomized, double-blind clinical trial of combination therapy with adalimumab plus 
methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive 
rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 
2006;54:26-37 
[76] Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with 
moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-
controlled trial. Arthritis Rheum 2005;52:3279-89 
[77] Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in 
active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005;64:1568-75 
[78] Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for 
dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab 
multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36  
[79] van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients 
with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). 
Arthritis Rheum 2005;52:582-91 
[80] Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic 
arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7 
 –30– 
[81] St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate 
therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 
2004;50:3432-43 
[82] Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, 
efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72 
[83] Rau R, Simianer S, van Riel PL, et al. Rapid alleviation of signs and symptoms of rheumatoid 
arthritis with intravenous or subcutaneous administration of adalimumab in combination with 
methotrexate. Scand J Rheumatol 2004;33:145-53  
[84] Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes 
of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in 
patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a 
randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11 
[85] van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as 
monotherapy in patients with rheumatoid arthritis for whom previous disease modifying 
antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16 
[86] Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in 
patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, 
placebo-controlled trial. Arthritis Rheum 2004;50:353-63 
[87] Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis 
factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the 
treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid 
Arthritis). J Rheumatol 2003;30:2563-71 
[88] van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour 
necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients 
with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168-77 
 –31– 
[89] Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor 
receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis 
Rheum 2003;48:3230-6 
[90] Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled 
trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 
2003;48:1667-75 
[91] Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis 
factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking 
concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45 
[92] Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor 
necrosis factor alpha. N Engl J Med 2002;346:1349-56  
[93] Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a 
randomised controlled multicentre trial. Lancet 2002;359:1187-93  
[94] Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of 
chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in 
active spondylarthropathy. Arthritis Rheum 2002;46:755-65 
[95] Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment 
of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with 
Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602 
[96] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and 
psoriasis: a randomised trial. Lancet 2000;356:385-90 
[97] Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha 
monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate 
therapy. J Rheumatol 2000;27:841-50 
[98] Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor 
necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving 
methotrexate. N Engl J Med 1999;34:253-9  
 –32– 
[99] Kim HY, Lee SK, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III 
study of the human anti-tumor necrosis factor antibody adalimumab administered as 
subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. 
APLAR Journal of Rheumatology 2007;10: 9-16  
[100] Zhang FC, Hou Y, Huang F, et al. Infliximab versus placebo in rheumatoid arthritis patients 
receiving concomitant methotrexate: A preliminary study from China. APLAR Journal of 
Rheumatology 2006;9:127-30  
[101] Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: 
longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the long-
term extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 
2012;89:90-3  
[102] Dougados M, Braun J, Szanto S, et al. Continuous efficacy of etanercept in severe and advanced 
ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. 
Rheumatology (Oxford) 2012;51:1687-96 
[103] Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with 
ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8 
[104] van der Heijde D, Burmester G, Melo-Gomes J, et al. The safety and efficacy of adding 
etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid 
arthritis patients previously treated with monotherapy. Ann Rheum Dis 2008;67:182-8  
[105] Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous 
infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose 
weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63  
[106] Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on 
safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217-9 ** Detailed rheumatoid 
arthritis guidelines on the safety of anti-TNF therapies.   
 –33– 
[107] Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments 
in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. 
Ann Rheum Dis 2009;68:1136-45 * Recent meta-analysis on the topic. 
[108] Bernatsky S, Habel Y, Rahme E. Observational studies of infections in rheumatoid arthritis: a 
meta-analysis of tumor necrosis factor antagonists. J Rheumatol 2010;37:928-31 *Recent meta-
analysis of observational studies on the topic. 
[109] Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious 
infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of 
randomized controlled trials. Arthritis Rheum 2011;63:1479-85 *Recent meta-analysis of 
observational studies on the topic. 
[110] Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of 
tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J 
Rheumatol Suppl 2014;91:47-55   
[111] van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients 
with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the 
Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895-900  
[112] Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious 
infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, 
etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012;12:225-9   
[113] Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis 
opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year 
prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23 
[114] Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with 
rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for 
Rheumatology Biologics Register. Ann Rheum Dis 2010;69:522-8  
[115] Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis 
factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: 
 –34– 
The three-year prospective French Research Axed on Tolerance of Biotherapies registry. 
Arthritis Rheum 2009;60:1884-94  
[116] Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-γ 
release assays: an update on the accuracy, cutoff stratification, and new potential immune-based 
approaches. J Rheumatol Suppl. 2014;91:24-31 
[117] Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent 
tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical 
practice. Autoimmun Rev. 2015;14(6):503-509 
[118] Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: 
from bench to bedside. J Microbiol Immunol Infect. 2014;47(4):268-74 
[119] Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. 
Rheumatology (Oxford). 2005;44(6):714-20. 
 
 –35– 
 
Legends for Figures 
 
Figure 1.  Summary of evidence search and selection (flow iagram). 
Abbreviations. RCTs: randomized controlled trials; OLEs: open label extension studies; AEs: adverse 
events. 
 
Figure 2.  Risk-of-bias assessments for the randomized trials included in the meta-analysis. 
Symbols. green (+): low risk of bias; yellow (?): unclear risk of bias; red (-): high risk of bias. 
 
Figure 3.  Forest plot for serious infections: results from individual studies and meta-analyses. 
Abbreviations. OR: odds ratio; CI: confidence interval. 
 
Figure 4A.  Contour-enhanced funnel plot for serious infections. 
Footnote. Ideally, the funnel plot should have a symmetrical shape with a wide base and a narrow peak. 
The figure indicates that smaller trials reporting odds ratios lower than the unity are probably missing, 
and thus the pooled effect estimate for serious infections may have been overestimated. Tests of 
publication bias: Begg’s p=0.07; Egger’s p=0.09. 
 
Figure 4B.  Contour-enhanced funnel plot for any infection. 
Footnote. Tests of publication bias: Begg’s p=0.95; Egger’s p=0.75. 
 
Figure 5.  Forest plot for tuberculosis: results from individual studies and meta-analyses. 
Abbreviations. OR: odds ratio; CI: confidence interval.  
 
Figure 6.  Forest plot for opportunistic infections: results from individual studies and meta-analyses. 
Abbreviations. OR: odds ratio; CI: confidence interval. 
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Figure 7.  Forest plot for any infection: results from individual studies and meta-analyses. 
Abbreviations. OR: odds ratio; CI: confidence interval. 
 
Figure 8. Log odds ratios of any infection as a function of the duration of follow-up. The greater the 
variance of a study, the smaller the area of the circle and the less that observation contributes to the 
overall effect. The superimposed line is obtained by meta-regression analysis. 
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Table 1. Characteristics of the RCTs included in the meta-analysis (n=71).  
 
 
 
Study Acronym Disease Study arms Intervention parameters 
Patients 
randomize
d 
Follow-
up 
duration 
(months) 
Age of 
patients 
(years) 
Disease 
duration 
(months) 
Abe et al., 2006 [74]  RA 
IFX+MTX 3 mg/kg, wk: 0,2,6 (n=49) 3.5 55.2 9.1 
IFX+MTX 10 mg/kg wk: 0,2,6 (n=51) 3.5 56.8 7.1 
PBO+MTX  (n=47) 3.5 55.1 7.5 
Antoni et al., 2005 [80] IMPACT 2 PsA 
IFX+MTX 5 mg/kg, wk: 0,2,6,14 (n=100) 6 47.1 100.8 
PBO+MTX  (n=100) 6 46.5 90.0 
Antoni et al., 2005 [78] IMPACT 1 PsA 
IFX+MTX 5 mg/kg, wk: 0,2,6,14 (n=52) 4 45.7 140.4 
PBO+MTX  (n=52) 4 45.2 132.0 
Baranauskaite et al., 2012 [46] RESPOND PsA 
IFX+MTX 5 mg/kg, wk: 0,2,6,14 (n=57) 4 40.1 33.6 
MTX  (n=58) 4 42.3 44.4 
Barkham et al., 2010 [49]  AS 
ETA+MTX 25 mg (n=20) 3 40.8 132.0* 
PBO+MTX  (n=12) 3 39.4 240.0* 
Bejarano et al., 2008 [61]  RA 
ADA+MTX NR (n=75) 56 47.0 9.5 
PBO+MTX   (n=73) 56 47.0 7.9 
Brandt et al., 2003 [90]  AS 
ETA 25 mg/2wk (n=16) 7.5 39.8 14.9 
PBO  (n=17) 7.5 32.0 11.4 
Braun et al., 2002 [93]  AS 
IFX 5 mg/kg, wk: 0,2,6 (n=34) 3 40.6 16.4 
PBO  (n=35) 3 39.0 14.9 
Breedveld et al., 2006 [75] PREMIER RA 
ADA+MTX 40 mg/2 wks (n=268) 24 51.9 8.4 
PBO+MTX  (n=257) 24 52.0 9.6 
Chen et al., 2009 [54]  RA 
ADA+MTX 40 mg/2 wks (n=35) 3 53.0* 74.4* 
PBO+MTX  (n=12) 3 53.0* 99.6* 
Choy et al., 2012 [44]  RA 
CTP+MTX 400 mg/4 wks (n=126) 6 53.0 9.4 
PBO+MTX  (n=121) 6 55.6 9.9 
Combe et al., 2009 [62]  RA 
ETA 25 mg/twice per wk (n=103) 24 50.6 78.0 
PBO  (n=101) 24 53.3 67.2 
Davis et al., 2003 [89]  AS ETA+DMARDs 25 mg/2 wks (n=138) 6 42.1* 10.1* 
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PBO+DMARDs  (n=139) 6 41.9* 10.5* 
Detert et al., 2013 [41]   RA 
ADA+MTX 40 mg eow (n=87) 6 47.2 1.8 
PBO+MTX  (n=85) 6 52.5 1.6 
Dougados et al., 2011 [50]  SPINE AS 
ETA+DMARDs 50 mg/wk (n=39) 3 46.0 228.0 
PBO+DMARDs  (n=43) 3 48.0 276.0 
Emery et al., 2009 [52] GO BEFORE RA 
GLM+MTX 100 mg/4 wks (n=159) 6 50.2 43.2 
GLM+MTX 50 mg/4 wks (n=159) 6 50.9 42.0 
PBO+MTX  (n=160) 6 48.6 34.8 
Emery et al., 2008 [63]  COMET RA 
ETA+MTX 50 mg/wk (n=274) 24 50.5 8.8 
PBO+MTX  (n=268) 24 52.3 9.3 
Fleischmann et al., 2012 [47]  RA 
ADA 40 mg eow (n=53) 6 54.0 7.7* 
PBO  (n=59) 6 53.0 10.8* 
Fleischmann et al., 2009 [58] FAST4WARD RA 
CTP 400 mg/4 wks (n=111) 6 52.7 104.4 
PBO  (n=109) 6 54.9 124.8 
Furst et al., 2003 [87]  STAR RA 
ADA+DMARDs 40 mg eow (n=318) 6 55.0 9.3 
PBO+DMARDs  (n=318) 6 55.8 11.5 
Genovese et al., 2007 [69]  PsA 
ADA+DMARDs 40 mg/2 wks (n=51) 3 50.4 90.0 
PBO+DMARDs  (n=49) 3 47.7 86.4 
Gorman et al., 2002 [92]  AS 
ETA+DMARDs 25 mg/2 wks (n=20) 4 38.0 180.0 
PBO+DMARDs  (n=20) 4 39.0 144.0 
Huang et al., 2014 [34]  AS 
ADA+DMARDs 40 mg (n=229) 3 30.1 36.0 
PBO+DMARDs   (n=115) 3 29.6 36.0 
Inman et al., 2008 [60] GO RAISE AS 
GLM+DMARDs 50 mg (n=138) 4 38.0* 61.8* 
GLM+DMARDs 100 mg (n=140) 4 38.0* 62.4* 
PBO+DMARDs  (n=78) 4 41.0* 87.0* 
Kavanaugh et al., 2013 [43] OPTIMA RA 
ADA+MTX 40 mg (n=515) 6 50.7 4.0 
PBO+MTX  (n=517) 6 50.4 4.5 
Kavanaugh et al., 2009 [55] GO REVEAL PsA 
GLM 50 mg/4 wks (n=146) 6 45.7 86.4 
GLM 100 mg/4 wks (n=146) 6 48.2 92.4 
PBO  (n=113) 6 47.0 91.2 
Kavanaugh et al., 2000 [97]  RA 
IFX+MTX 5 mg/kg single injection (n=7) 3 47.0 88.8 
IFX+MTX 10 mg/kg single injection (n=7) 3 53.0 90.0 
IFX+MTX 20 mg/kg single injection (n=7) 3 37.4 58.8 
PBO+MTX  (n=7) 3 44.6 58.8 
Kay et al., 2008 [64]   RA GLM+MTX 50 mg/4 wks (n=35) 5 57.0* 98.4* 
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GLM+MTX 50 mg/2 wks (n=34) 5 48.0* 98.4* 
GLM+MTX 100 mg/4 wks (n=34) 5 57.5* 75.6* 
GLM+MTX 100 mg/2 wks (n=34) 5 53.5* 108.0* 
PBO+MTX  (n=35) 5 52.0* 67.2* 
Keystone et al., 2009 [56]  GO FORWARD RA 
GLM+MTX 100 mg/4 wks (n=89) 3.5 50.0* 80.4* 
GLM+MTX 50 mg/4 wks (n=89) 3.5 52.0* 54.0* 
PBO+MTX  (n=133) 3.5 52.0* 78.0* 
Keystone et al., 2008 [59] RAPID 1 RA 
CTP+MTX 200 mg/2 wks (n=393) 13 51.4 73.2 
CTP+MTX 400 mg/2 wks (n=390) 13 52.4 74.4 
PBO+MTX  (n=199) 13 52.2 74.4 
Keystone et al., 2004 [84]  RA 
ADA+MTX 40 mg eow (n=419) 4.3 56.1 11.0 
PBO+MTX  (n=200) 4.3 56.1 10.9 
Keystone et al., 2004 [86]  RA 
ETA+MTX 50 mg/wk (n=214) 2 53.0* 9.0* 
ETA+MTX 25 mg/2 wks (n=153) 2 52.0* 8.2* 
PBO+MTX  (n=53) 2 54.0* 10.8* 
Kim et al., 2007 [99]  RA 
ADA+MTX 40 mg (n=65) 6 48.5 6.8 
PBO+MTX  (n=63) 6 49.8 6.9 
Kremer et al., 2010 [51]   RA 
GLM+MTX 2 mg/kg, wk: 0,12,24,36,48 (n=129) 12 49.7 97.2 
GLM+MTX 4 mg/kg, wk: 0,12,24,36,48 (n=128) 12 49.6 112.8 
PBO+MTX  (n=129) 12 50.2 88.8 
Landewè et al., 2014 [31] RAPID AS 
CTP+MTX 200 mg/wk: 0,2,4 (n=111) 6 39.1 NR 
CTP+MTX 400 mg/wk: 0,2,4 (n=107) 6 39.8 NR 
PBO+MTX  (n=107) 6 39.9 NR 
Leirisalo-Repo et al., 2013 [40] NEO RACO RA 
IFX 3 mg/kg/wk: 4,6,10,18,26 (n=50) 24 47.0 4.0 
PBO  (n=49) 24 46.0 4.0 
Lipsky et al., 2000 [95] ATTRACT RA 
IFX+MTX 3 mg/kg/4 wks (n=86) 13.5 52.0 9.0 
IFX+MTX 10 mg/kg/8 wks (n=87) 13.5 54.0 11.0 
IFX+MTX 10 mg/kg/4 wks (n=81) 13.5 52.0 12.0 
IFX+MTX 3 mg/kg/8 wks (n=86) 13.5 54.0 10.0 
PBO+MTX  (n=88) 13.5 51.0 11.0 
Marzo-Ortega et al., 2005 [77]  AS 
IFX+MTX 5 mg/kg/wk: 0,2,6,14,22 (n=28) 7.5 41* 8* 
PBO+MTX  (n=14) 7.5 39* 10* 
Mease et al., 2014 [32] RAPID PsA PsA 
CTP+MTX 200 mg/2 wks (n=138) 6 48.2 115.2 
CTP+MTX 400 mg/4 wks (n=135) 6 47.1 97.2 
PBO+MTX  (n=136) 6 47.3 94.8 
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Mease et al., 2005 [75]  PsA 
ADA+MTX 40 mg/2 wk (n=151) 6 48.6 117.6 
PBO+MTX  (n=162) 6 49.2 110.4 
Mease et al., 2004 [82]  PsA 
ETA+MTX 25 mg/twice wk (n=87) 6 47.6 108.0 
PBO+MTX  (n=81) 6 47.3 110.4 
Mease et al., 2000 [96]   PsA 
ETA+MTX 25 mg/twice wk (n=30) 3 46.0* 108* 
PBO+MTX  (n=30) 3 43.5* 114* 
Miyasaka et al., 2008 [65] CHANGE RA 
ADA 80 mg/2 wks (n=87) 6 54.3 114.0 
ADA 40 mg/2 wks (n=91) 6 56.9 118.8 
ADA 20 mg/2 wks (n=87) 6 54.8 120.0 
PBO  (n=87) 6 53.4 100.8 
Rau et al., 2004 [83] 
 
 RA 
ADA+MTX 1 mg/Kg (iv) 0, 29 week  (n=18) 1.5 52.3 133.2 
ADA+MTX 1 mg/Kg (sc) 0, 29 week  (n=18) 1.5 53.3 127.2 
PBO+MTX  (n=18) 1.5 54.1 138.0 
Schiff et al., 2008 [66] ATTEST RA 
IFX+MTX 0-3 mg/kg/8 wks (n=165) 6 49.1 87.6 
PBO+MTX  (n=110) 6 49.4 100.8 
Sieper et al., 2014 [33] INFAST AS 
IFX 5 mg/kg, wk: 0,2,6,12,18,24 (n=106) 7 31.7 10.1 
PBO  (n=52) 7 30.7 8.3 
Sieper et al., 2013 [39] ABILITY 1 AS 
ADA+DMARDs 40 mg/1wk (n=91) 3 37.6 36.0 
PBO+DMARDs  (n=94) 3 38.4 32.4 
Smolen et al., 2009 [57] RAPID 2 RA 
CTP+MTX 400 mg/2 wks (n=246) 3 51.9 78.0 
CTP+MTX 200 mg/2 wks (n=246) 3 52.2 73.2 
PBO+MTX  (n=127) 3 51.5 67.2 
Smolen et al., 2009 [53] GO AFTER RA 
GLM+DMARDs 50 mg/4 wks (n=153) 4 55.0* 115.2* 
GLM+DMARDs 100 mg/4 wks (n=153) 4 55.0* 104.4* 
PBO+DMARDs  (n=155) 4 54.0* 117.6* 
Smolen et al., 2013 [30] PRESERVE RA 
ETA+MTX 50 mg (n=202) 12 48.1 81.6 
ETA+MTX 25 mg (n=202) 12 46.4 76.8 
PBO+MTX  (n=200) 12 48.3 87.6 
St Clair et al., 2004 [81]  RA 
IFX+MTX 3 mg/kg/4 wks (n=373) 13.5 51.0 10 
IFX+MTX 6 mg/kg/4 wks (n=376) 13.5 50.0 11 
PBO+MTX  (n=298) 13.5 50.0 11 
Takeuchi et al., 2014 [35] HOPEFUL 1 RA 
ADA+MTX 40 mg eow (n=171) 6.5 54.0 3.6 
PBO+MTX   (n=163) 6.5 54.0 3.6 
Takeuchi et al., 2013 [36] GO-MONO RA 
GLM 50 mg every 4 w (n=102) 4 52.9 97.2 
GLM 100 mg every 4 w (n=104) 4 51.6 112.8 
 –50– 
PBO  (n=110) 4 52.4 110.4 
Tanaka et al., 2012 [45] GO-FORTH RA 
GLM+MTX 50 mg, wk: 0, 4, 8, 12, 16, 20, 24 (n=89) 6 50.4 105.6 
GLM+MTX 100 mg, wk: 0, 4, 8, 12, 16, 20, 24 (n=90) 6 50.0 97.2 
PBO+MTX   (n=90) 6 51.1 104.4 
Van de Putte et al., 2004 [85]  RA 
ADA 20 mg eow (n=106) 6.5 53.1 111.6 
ADA 20 mg weekly (n=112) 6.5 54.4 135.6 
ADA 40 mg eow (n=113) 6.5 52.7 127.2 
ADA 40 mg weekly (n=103) 6.5 51.8 142.8 
PBO  (n=110) 6.5 53.5 139.2 
Van de Putte et al., 2003 [88]  RA 
ADA 20 mg weekly (n=72) 3 53.7 10.4 
ADA 40 mg weekly (n=70) 3 52.6 10.0 
ADA 80 mg weekly (n=72) 3 53.2 10.1 
PBO  (n=70) 3 50.2 9.4 
Van den Bosch et al., 2002 [94]  AS 
IFX 5 mg/kg, wk: 0,2,6 (n=20) 3 46.0* 78.0* 
PBO  (n=20) 3 47.5* 96.0* 
Van der Heijde et al., 2007 [67] TEMPO RA 
ETA+MTX 25 mg/2w (n=231) 36 52.5 6.8 
MTX  (n=228) 36 53.0 6.8 
Van der Heijde et al., 2006 [71]  AS 
ETA+DMARDs 50 mg/once weekly (n=155) 3 41.5 108.0  
ETA+DMARDs 25 mg/twice weekly (n=150) 3 39.8 120.0 
PBO+DMARDs  (n=51) 3 40.1 102.0 
Van der Heijde et al., 2006 [72] ATLAS AS 
ADA+DMARDs 40 mg/2wk (n=208) 6 41.7 11.3 
PBO+DMARDs  (n=107) 6 43.4 10.0 
Van der Heijde et al., 2005 [79] ASSERT AS 
IFX 5 mg/kg, wk: 0,2,6,12,18 (n=201) 6 40.0* 92.4* 
PBO  (n=78) 6 41.0* 158.4* 
Van Vollenhoven et al., 2012 [38] ORAL standard RA 
ADA+MTX 40 mg/2wk (n=204) 3 52.5 97.2 
PBO+MTX  (n=108) 3 53.7 79.5 
Van Vollenhoven et al., 2011 [48] AUGUST II RA 
ADA+MTX 40 mg/2wk (n=79) 9.5 53.0 105.6 
PBO+MTX  (n=76) 9.5 54.0 100.8 
Weinblatt et al., 2013 [42] GO-FURTHER RA 
GLM+MTX 2 mg/kg, wk: 0,4 and every 8 wk (n=395) 4 51.9 82.8 
PBO+MTX  (n=197) 4 51.4 84.0 
Weinblatt et al., 2012 [37] REALISTIC RA 
CTP 400 mg/wk: 0,2,4 then 200 mg/2wk (n=851) 3 55.4 103.2 
PBO  (n=212) 3 53.9 106.8 
Weinblatt et al., 2003 [91] ARMADA RA 
ADA+MTX 20 mg/2wk (n=69) 6 53.5 157.2 
ADA+MTX 40 mg/2wk (n=67) 6 57.2 146.4 
ADA+MTX 80 mg/2wk (n=73) 6 55.5 153.6 
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PBO+MTX  (n=62) 6 56.0 133.2 
Weinblatt et al., 1999 [98]  RA 
ETA+MTX 25 mg/twice wk (n=59) 6 48 156 
PBO+MTX  (n=30) 6 53 156 
Weisman et al., 2007 [68]  RA 
ETA+DMARDs 25 mg/twice wk (n=266) 4 60.6* 121.2* 
PBO+DMARDs  (n=269) 4 59.3* 112.8* 
Westhovens et al., 2006 [73]  RA 
IFX+MTX 3 mg/kg, wk: 0, 2, 6, 14 (n=360) 5.5 53.0* 93.6* 
IFX+MTX 10 mg/kg, wk: 0, 2, 6, 14 (n=361) 5.5 52.0* 75.6* 
PBO+MTX  (n=363) 5.5 52.0* 100.8* 
Zhang et al., 2006 [100]  RA 
IFX+MTX 3 mg/kg, wk: 0, 2, 6, 14 (n=87) 4.5 47.9 85.6 
PBO+MTX  (n=86) 4.5 48.9 96.0 
Zhou et al., 2007 [70]  RA 
GLM+DMARDs 0.1 mg/kg (n=3) 4 48.0 NR 
GLM+DMARDs 0.3 mg/kg (n=3) 4 44.0 NR 
GLM+DMARDs 1 mg/kg (n=5) 4 43.0 NR 
GLM+DMARDs 3 mg/kg (n=5) 4 67.0 NR 
GLM+DMARDs 6 mg/kg (n=5) 4 50.0 NR 
GLM+DMARDs 10 mg/kg (n=5) 4 46.0 NR 
PBO+DMARDs  (n=10) 4 60.0 NR 
 
Abbreviations.  ADA: adalimubab;  AS: ankylosing spondylitis;  CTP: certolizumab pegol;  DMARDs: disease-modifying anti-rheumatic drugs;  eow: every other week;  
ETA: etanercept;  GLM: golimubab;  IFX: infliximab;  MTX: methotrexate;  NR: not reported;  PsA: psoriatic arthritis;  PBO: placebo;  RA: rheumatoid arthritis;  wk: week.  
 
Footnote.  Mean values are given for "age of patients" and "disease duration", or median values when indicated with an asterisk.  
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Table 2.  Meta-analysis results.   
  Fixed-effects model Random-effects model Tests of homogeneity Tests of publication bias 
 No. of studies OR (95% CI) OR (95% CI) Q value (d.f.) P-value  I2 Begg’s p-value Egger’s p-value 
           
Serious Infections           
  ‒ All RCTs  58 1.41 (1.16, 1.73) 1.25 (1.01, 1.55) 48.48 (57) 0.78 0% 0.06 0.09 
  ‒ RCT high-dose arms* 58 1.46 (1.19, 1.79) 1.36 (1.09, 1.69) 45.68 (57) 0.86 0% 0.25 0.16 
  ‒ OLE studies 6 1.33 (0.77, 2.29) 1.19 (0.68, 2.07) 4.39 (5) 0.49 0% 0.45 0.22 
Tuberculosis            
  ‒ All RCTs  19 3.53 (1.58, 7.85) 3.29 (1.48, 7.33) 0.62 (18) 0.99 0% 0.94 0.05 
  ‒ RCT high-dose arms* 19 3.32 (1.54, 7.15) 3.23 (1.50, 6.98) 0.48 (18) 0.99 0% 0.03 0.07 
Opportunistic Infections           
  ‒ All RCTs  6 0.94 (0.33, 2.64) 0.81 (0.23, 2.87) 3.32 (5) 0.65 0% 0.13 0.12 
  ‒ RCT high-dose arms* 6 0.98 (0.35, 2.73) 0.87 (0.25, 3.00) 3.59 (5) 0.61 0% 0.02 0.16 
Any Infection            
  ‒ All RCTs  37 1.20 (1.10, 1.30) 1.20 (1.06, 1.36) 66.45 (36) <0.01 46% 0.95 0.75 
  ‒ RCT high-dose arms* 37 1.21 (1.11, 1.32) 1.22 (1.07, 1.39) 67.44 (36) <0.01 47% 0.80 0.74 
  ‒ OLE studies 6 1.69 (1.31, 2.18) 1.56 (1.05, 2.33) 9.11 (5) 0.10 45% 0.26 0.61 
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RCTs: randomized controlled trials;  OLE: open label extension;  OR: odds ratio;  CI: confidence interval;  d.f.: degrees of freedom.   
*analysis using (from the multi-arm trials) only the data referring to the intervention arm exposed to the highest dose.   
 –54– 
 
Table 3. Summary of findings.  
 
 
Population:  Adult patients with rheumatologic disease (rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis)   
Intervention:  Anti-TNF drugs (adalimumab, certolizumab, etanercept, golimumab, or infliximab)  
Comparison:  Placebo or no treatment  
Follow-up:  1–36 months (8 months per patient, on average) 
 
Illustrative comparative risks (95% CI) 
 Assumed risk Corresponding risk 
PBO or no treatment Anti-TNF drugs 
Serious Infections 20 per 1000 
28 per 1000  
(23 to 34) Relative effect (95% CI):  OR, 1.41 (1.16, 1.73)  
No. of participants: 20,796   
No. of RCTs: 58 
Quality of the evidence (GRADE): ⊕⊕⊕⊝ (Moderate)  
 
Opportunistic Infections 3 per 1000 
3 per 1000  
(1 to 8) Relative effect (95% CI):  OR, 0.94 (0.33, 2.64)  
No. of participants: 3,886   
No. of RCTs: 6 
Quality of the evidence (GRADE): ⊕⊕⊝⊝ (Low)  
 
Any Infection 285 per 1000 
324 per 1000  
(305 to 341) Relative effect (95% CI):  OR, 1.20 (1.10, 1.30)  
No. of participants: 12,796   
No. of RCTs: 37 
Quality of the evidence (GRADE): ⊕⊕⊕⊝ (Moderate)  
 
Footnotes:  
(i) the basis for the assumed risk is the overall event occurrence across RCT control groups,  
(ii) the corresponding risk is based on the assumed risk in the comparison group and the relative effect of the intervention,  
(iii) the relative effect and its 95% CI come from a fixed-effects meta-analytic model,  
(iv) a corresponding risk could not be estimated for Tuberculosis, because no event was reported in the control groups,  
(v) the overall quality of the synthesized evidence is “moderate” for the following reasons: Data was derived from RCTs (randomized 
study design is considered the gold standard for assessing drugs); the meta-analytic effect estimates are precise (except for opportunistic 
infections); the results are consistent (heterogeneity was low or moderate across studies); and all the RCTs included in meta-analysis are 
characterized by high or unclear RoB in several important quality domains, such as allocation concealment and incomplete outcome data 
(a fact that downgrades the quality of evidence). A moderate quality of evidence means that “we are moderately confident in the effect 
estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different”. 
(vi) explanations for Summary of findings Tables can be found at: www.thecochranelibrary.com/view/0/SummaryFindings.html   
 
Abbreviations. CI: confidence interval; OR: odds ratio; PBO: placebo; RoB: risk of bias.  
 
